A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Hereditary Angioedema (HAE)
Interventions
OTHER

No intervention

This is a non-interventional study.

Trial Locations (13)

110001

The First Hospital of China Medical University, Shenyang

200011

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

250014

Qianfo Mountain Hospital, Shandong Province, Jinan

310009

The Second Affiliated hospital Zhejiang University School of Medicine, Hangzhou

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

430030

Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology, Wuhan

450003

Henan Provincial People's Hospital, Zhengzhou

510080

The First Affiliated Hospital ,Sun Yat-sen University, Guangzhou

510260

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

610041

West China Hospital of Sichuan University, Chengdu

650032

First Affiliated hospital of Kunming Medical University, Kunming

710000

The Second Affiliated hospital of Xian Jiaotong University, Xian

030032

Shanxi Bethune hospital, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY